EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bellmunt risk score enables survival prediction in men with metastatic castration resistant prostate cancer (mCRPC) undergoing PSMA-targeted radioligand therapy (LUMEN)

Thomas Büttner, Milka Marinova iD, Florian C Gaertner, Barbara Kreppel, Leander Fritsche, Christian Immanuel, Gerd Geraths, Stefan Kürpig, Jim Küppers, Ingo G H Schmidt-Wolf, Markus Essler, Manuel Ritter und 1 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-025-07492-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Thomas Büttner und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Heterocyclic Compounds, 1-Ring, Dipeptides, Glutamate Carboxypeptidase II. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Bonn.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose [ 177 Lu]Lu-PSMA-617 therapy has emerged as a promising radioligand treatment for metastatic castration-resistant prostate cancer (mCRPC). Given the overall poor prognosis of mCRPC, accurately predicting the key endpoint overall survival (OS) remains an ongoing challenge, crucial for optimizing risk/benefit assessment prior to treatment. This study investigates the prognostic utility of the simple designed Bellmunt Risk Score (BRS) in mCRPC patients treated with [ 177 Lu]Lu-PSMA-617.

Methods

We retrospectively evaluated data from 386 mCRPC patients who had received [ 177 Lu]Lu-PSMA-617 therapy at our center. BRS was constructed by attributing one point for each of the following risk factors: ECOG performance status (ECOG PS) > 0, hemoglobin < 10 g/dL, and the presence of liver metastases. Additionally, an enhanced version of the score including C-reactive protein (CRP) > 30 mg/dL and a modified version utilizing a semi-quantitative ECOG PS were developed. Statistical analysis included Cox regression, Kaplan-Meier estimates, concordance indices and time-dependent area under the curve (tAUC).

Results

The BRS served as an independent predictor of OS in multivariable analysis. The estimated median OS was 17.6, 10.9, 6.6, and 2.7 months for patients with scores of 0, 1, 2 and 3, respectively (Log-Rank P < 0.001). The tAUC values for predicting 1-year and 2-year OS were 71.6% and 74.4%, respectively. The CRP-enhanced score further improved prognostic accuracy, achieving tAUCs of 75.7% for 1-year OS and 78.1% for 2-year OS.

Conclusion

The Bellmunt Risk Score effectively stratifies mCRPC patients undergoing [ 177 Lu]Lu-PSMA-617 therapy. Its straightforward design, based on readily accessible clinical parameters, ensures practicality and utility in real-world clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantHeterocyclic Compounds, 1-RingDipeptidesGlutamate Carboxypeptidase IIHumansMaleAgedRetrospective StudiesMiddle AgedLutetiumAged, 80 and overNeoplasm MetastasisPrognosisRisk AssessmentRadiopharmaceuticalsAntigens, SurfaceRadioisotopesProstate-Specific Antigen

Stichwörter der Autor:innen

Bellmunt Risk ScoreLutetiumPSMAPredictionSurvivalmCRPC

Substanzen

Heterocyclic Compounds, 1-RingDipeptidesLutetiumGlutamate Carboxypeptidase IIFOLH1 protein, humanLutetium-177RadiopharmaceuticalsPluvictoAntigens, SurfaceRadioisotopes

Autor:innen und Institutionen

  • Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.
  • Department of Nuclear Medicine, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany. Milka.Marinova@ukbonn.de.
  • Department of Nuclear Medicine, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
  • Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany.

ORCID-Profile: Milka Marinova

Förderung

  • Universitätsklinikum Bonn

Zitieren

APA

Büttner, T., Marinova, M., Gaertner, F. C., Kreppel, B., Fritsche, L., Immanuel, C., Geraths, G., Kürpig, S., Küppers, J., Schmidt-Wolf, I. G. H., Essler, M., Ritter, M., & Krausewitz, P. (2026). Bellmunt risk score enables survival prediction in men with metastatic castration resistant prostate cancer (mCRPC) undergoing PSMA-targeted radioligand therapy (LUMEN). European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07492-9

Vancouver

Büttner T, Marinova M, Gaertner FC, Kreppel B, Fritsche L, Immanuel C, et al. Bellmunt risk score enables survival prediction in men with metastatic castration resistant prostate cancer (mCRPC) undergoing PSMA-targeted radioligand therapy (LUMEN). European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07492-9

BibTeX
@article{Bttner2026,
  author = {Büttner, Thomas and Marinova, Milka and Gaertner, Florian C and Kreppel, Barbara and Fritsche, Leander and Immanuel, Christian and Geraths, Gerd and Kürpig, Stefan and Küppers, Jim and Schmidt-Wolf, Ingo G H and Essler, Markus and Ritter, Manuel and Krausewitz, Philipp},
  title = {Bellmunt risk score enables survival prediction in men with metastatic castration resistant prostate cancer (mCRPC) undergoing PSMA-targeted radioligand therapy (LUMEN)},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-025-07492-9}
}
Kostenlos starten →